Foundation for Women’s Cancer | Strategic Alliance Partners

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.

The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.

Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.

Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.

Ginger J. Gardner, MD, FACOG, walked through the strides of gynecologic cancer research and emphasized the efforts that still need to be accomplished.

The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.

Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.

Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.